251 related articles for article (PubMed ID: 22777612)
1. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
Corona G; Rastrelli G; Maseroli E; Balercia G; Sforza A; Forti G; Mannucci E; Maggi M
J Endocrinol Invest; 2012 Nov; 35(10):915-20. PubMed ID: 22777612
[TBL] [Abstract][Full Text] [Related]
2. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
Gur S; Kadowitz PJ; Hellstrom WJ
Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
[TBL] [Abstract][Full Text] [Related]
3. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
4. Re: inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
Kaplan SA
J Urol; 2014 Mar; 191(3):752. PubMed ID: 24522062
[No Abstract] [Full Text] [Related]
5. 5-alpha reductase inhibitors and erectile dysfunction: the connection.
Erdemir F; Harbin A; Hellstrom WJ
J Sex Med; 2008 Dec; 5(12):2917-24. PubMed ID: 19090946
[TBL] [Abstract][Full Text] [Related]
6. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
7. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
[TBL] [Abstract][Full Text] [Related]
8. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
Fertig RM; Gamret AC; Darwin E; Gaudi S
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
[TBL] [Abstract][Full Text] [Related]
9. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
[TBL] [Abstract][Full Text] [Related]
10. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.
Coskuner ER; Ozkan B; Culha MG
Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
12. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
13. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.
La Vignera S; Aversa A; Cannarella R; Condorelli RA; Duca Y; Russo GI; Calogero AE
Expert Opin Pharmacother; 2021 Feb; 22(2):179-189. PubMed ID: 32902360
[TBL] [Abstract][Full Text] [Related]
15. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia.
Traish AM; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2015 Sep; 23(3):85-96. PubMed ID: 26053014
[TBL] [Abstract][Full Text] [Related]
16. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy.
Oztekin CV; Gur S; Abdulkadir NA; Lokman U; Akdemir AÖ; Cetinkaya M; Hellstrom WJ
J Sex Med; 2012 Jul; 9(7):1773-81. PubMed ID: 22568670
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
Kuritzky L
Compr Ther; 2005; 31(3):194-208. PubMed ID: 16110128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
